Who should get these new shots? When will they be available? And why should you consider one?
Here’s everything you need to know about the bivalent boosters.
These new bivalent vaccines carry instructions to help our cells make defenses against two strains of the virus that causes Covid-19. The shots direct cells to make antibodies that bind to certain parts of the spike proteins from both the original strain of the SARS-CoV-2 virus and the BA.4 and BA.5 Omicron subvariants, which share an identical spike.
BA.4 and BA.5 are the dominant variants in the United States, causing an average of 91,000 new infections each day.
“These are vaccines that are made, manufactured and delivered identically to the Covid mRNA vaccines that most of us have already gotten,” said Dr. Gregory Poland, who leads the vaccine research group at Mayo Clinic in Rochester, Minnesota. “In a sense, you’ve just changed the blueprints.”
Having twice the blueprints doesn’t mean you’re getting twice the dose of active ingredients, though.
“The total mRNA content — the business part of the vaccine — that leads to the immune response is the same amount,” said Dr. William Gruber, senior vice president of vaccine research and development at Pfizer, which makes one of the updated vaccines.
Pfizer’s booster is a 30-microgram dose that contains 15 micrograms of mRNA against the ancestral strain and 15 micrograms against the BA.4 and BA.5 variants. It is authorized for people as young as 12.
The company is also retooling its shots for children ages to 5 through 11 and will ask the FDA for authorization of those updated boosters in early October. It’s working with the FDA to update vaccines for children ages 6 months through 4 years.
Moderna’s bivalent booster is a 50-microgram dose, with 25 micrograms of mRNA designed to fight the ancestral strain of the coronavirus and 25 micrograms of mRNA designed to fight the BA.4 and BA.5 variants. It’s authorized for people 18 and older.
Where and when can I get an updated Covid-19 booster?
The government has already been taking orders for these vaccines, and now that the FDA has authorized them, millions of doses will ship to tens of thousands of sites across the country. These include community health centers, health departments and pharmacies.
As with past Covid-19 vaccines, these shots will be available free of charge. But they may be some of the last Covid-19 freebies from the government, which has said it’s going to start commercializing treatments and vaccines this fall.
Pfizer says it has the capacity to ship up to 15 million doses by September 9.
The panel of experts that advises the US Centers for Disease Control and Prevention on its vaccine recommendations reviewed the science behind the shots Thursday and voted to recommend them. CDC Director Dr. Rochelle Walensky then signed off, meaning people can start getting the shots right away.
“What I’m expecting is, after CDC action, you’ll start seeing some places start giving some shots in arms over the weekend, but very relatively few because [of the] Labor Day weekend. And my expectation is over next week, or certainly over the next 10 days, you’re going to start seeing these bivalent vaccines become widely available across the country,” Dr. Ashish Jha, who leads the White House Covid-19 Response Team, told CNN.
The government is also preparing to launch a campaign that will urge Americans to get their annual flu shot along with an updated Covid-19 booster. Research on this approach suggests that it’s safe.
The updated Covid-19 inoculations will be the only game in town when it comes to boosters, at least for those 12 and up. The FDA says the older boosters are no longer authorized for this age group but will still be available as boosters for children ages 5 to 11.
How do we know the updated Covid-19 vaccines work?
These are the first Covid-19 vaccines that will be authorized for use in people after being tested only in mice. This is much the same process that’s followed each year when annual flu shots are updated.
The FDA allowed companies to submit data from animal tests in order to speed these shots to the public. Studies in people are underway, according to Pfizer’s Gruber.
Dr. Peter Marks, who directs the FDA’s Center for Biologics Evaluation and Research, said he expects that it will be a month or two before data on humans is available.
Officials say urgency with these boosters is warranted going into the fall, when Covid-19 is still circulating at high levels and influenza is expected to make a return.
But the decision to rely on animal studies has generated some controversy.
Some vaccine experts feel that animal studies don’t provide sufficient evidence for these vaccines at this stage in the pandemic.
“You’re asking people to get a new product for which there’s no data,” Dr. Paul Offit, who directs the vaccine education center at Children’s Hospital of Philadelphia, told CNN. “Mice data are not adequate to launch 100-plus-billion-dose effort.”
Offit says it makes sense to use data from animal studies for updates to annual flu vaccines because we’ve used those shots for decades, and we understand what biomarkers to look for when gauging whether they work. These so-called correlates of protection are not as well understood for the Covid-19 vaccines.
It’s not just the shots that are different, Poland said. At this point in the pandemic, our immune systems are, too. Nearly all Americans have been infected with the coronavirus, vaccinated or both. Some people have had four or five doses of vaccine.
“So if you say to me, ‘can you assure me that getting dose five or dose six of this new vaccine in the background of having received these previous doses is absolutely safe?’ I’d say ‘no, I can’t.’ We’re extrapolating. And I think we ought to be clear about that,” Poland said.
FDA officials point out that animal studies weren’t the only data they reviewed to make their decision. They considered two other lines of evidence.
The first is the vaccines’ track records. The same basic vaccines have now been given to hundreds of millions of people around the world. They have been shown to be extremely effective at preventing severe disease and death from Covid-19. Risks associated with mRNA vaccination are very, very low.
The second line of evidence comes from bivalent vaccines that may soon be used in Europe.
Earlier this year, Pfizer and Moderna presented an independent panel of experts who advise the FDA with data on a bivalent vaccine designed to target the original strain of Omicron, BA.1. That data showed that the vaccines boosted antibody responses and were well-tolerated. The UK has authorized these vaccines, but they will not be available in the US.
The BA.1 strain isn’t circulating any more, and the FDA asked the manufacturers to update their US shots to include BA.4 and BA.5 instead.
Marks said in a briefing Wednesday that some evidence suggests that the BA.4 and BA.5 strains generate a stronger immune response than BA.1, which is another reason officials wanted to include them in the updated shots.
FDA Commissioner Dr. Robert Califf said he understands that people may want to know more, but he’s confident that these vaccines are safe and effective.
“It’s fair for people to raise questions. But this really is the best consensus that we have among the experts that this is the best way to go. … It’s just painful to see people dying unnecessarily when there’s a free treatment that would prevent their death,” he said.
“I will be at the front of the line at the pharmacy getting my vaccination,” said Califf, who will turn 71 next month. “I’m very confident about this.”
In the past, tests of variant-specific vaccines have had lackluster results. It’s hard to know what effect these bivalent vaccines could have.
They found that people got the biggest benefits from getting boosted, period. A booster against the ancestral strain of the virus that causes Covid-19 increased neutralizing antibodies 11-fold. The scientists estimated that would increase a person’s protection against symptomatic infection over the next six months from 50% to 86.5%.
Variant-specific boosters worked a little better, but the difference wasn’t dramatic. After those shots, protection against symptomatic infection over the next six months rose to 90.2%, just a 4.6% increase.
Are Covid-19 boosters safe?
Very rarely, mRNA vaccines can cause myocarditis, or swelling in or around the heart. After more than 80 million booster doses given in the United States, the government safety surveillance systems received 37 verifiable reports of myocarditis. Most of these were in men.
Marks said that to minimize this risk, officials are directing that the vaccines be given at least two months after a previous dose.
“It seems to be associated when they’re given closer to one another,” he said.
Why are new shots needed?
The Covid-19 vaccines were due for an update.
As the coronavirus has been circulating, it has changed a lot. These changes have helped it slip past the antibodies that we made against older versions of the virus and older versions of the vaccine. As a result, it’s gotten better at causing reinfections and breakthrough infections. Some of the monoclonal antibodies made to give people passive immunity against the virus have also stopped working against the new variants.
The hope is that giving people updated vaccines will improve their ability to fight off the infection and shore up protection against severe disease that causes hospitalization or death.
There is also some hope that updated boosters may slow the spread of the virus — and thus the speed at which vaccine-busting variants appear.
The coronavirus is changing at blistering speed. In a meeting with FDA vaccine advisers last June, Trevor Bedford, a professor of epidemiology and biostatistics at Fred Hutchinson Cancer Reserach Center in Seattle, compared the speed of evolution of the viruses that cause Covid-19 to that of the viruses that cause influenza.
Among the faster influenza viruses, he said, it takes about three years for a new strain to emerge and start showing up in testing in significant numbers. Among the variants of the virus that causes Covid-19, the Delta variant pulled off this feat in a year. Omicron did it in three to four months.
So there is genuine concern that without something to slow transmission of the infection, we’ll be forever stuck in catchup mode, waiting for faster and potentially more dangerous variants to emerge.
CNN Senior Medical Correspondent Elizabeth Cohen contributed to this report.